ERBB2 and breast carcinoma: For example, SMs targeting multiple IAPs promote apoptosis in response to the ERBB antagonists, trastuzumab, lapatinib, or gefitinib, in Her2-overexpressing breast cancer cells, or gefitinib in EGFR-overexpressing breast cancer cells [118].